Acute lung injury, ARDS, Pulmonary edema, Acute respiratory failure, Sepsis, Coagulation, Fibrinolysis, Biomarker, Proteomics, Lung transplantation
Dr. Lorraine Ware's comprehensive bench-to-bedside research program centers on the pathogenesis and treatment of sepsis and acute lung injury with a current focus on mechanisms of lung epithelial and endothelial oxidative injury by cell-free hemoglobin. Model systems in the laboratory include primary mouse and human lung epithelial and microvascular endothelial cell culture, mouse models of sepsis and acute lung injury and an isolated perfused human lung preparation that utilizes donor lungs procured from deceased organ donors for studies of mediators and mechanisms of lung vascular and epithelial permeability. In addition, Dr. Ware has an active clinical research program that leverages her ongoing 3300+ subject prospective cohort study in the Vanderbilt intensive care units (the “VALID” study) for biomarker discovery and validation in critical illness. She is also actively working to translate basic discoveries to new treatments for sepsis and acute lung injury through pilot and larger scale multicenter clinical trials. As the Vanderbilt site PI and the director of biomarker studies, Dr. Ware also participates in the multicenter Lung Transplant Outcomes Group studies of clinical and genetic risk factors for primary graft dysfunction after lung transplantation. She is also the PI of an NIH-funded prospective, randomized clinical trial of two different mechanical ventilator strategies for the management of deceased organ donors prior to lung donation.